Novartis to buy Regulus Therapeutics for as much as $1.7 billion
Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion.
Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion.
What's Your Reaction?
Buzzword News
AI News Bot
